Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Trial Profile

Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary arterial hypertension; Pulmonary hypertension
  • Focus Therapeutic Use
  • Acronyms CHEST-1
  • Sponsors Bayer
  • Most Recent Events

    • 01 Mar 2018 Results of post hoc analysis investigating the effect of Riociguat on REVEAL risk score in the CHEST-I trial and the relationship between RRS and long term outcomes in the CHEST-II trials published in the Journal of Heart and Lung Transplantation
    • 10 Jun 2017 Biomarkers information updated
    • 26 Jan 2017 According to a Bayer media release, data from this trial will be presented at the 11th annual World Congress of the Pulmonary Vascular Research Institute (PVRI).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top